Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

• Hauptverfasser: Ke Li (Verfasst von), Wenhua Zhan (Verfasst von), Yulong Chen (Verfasst von), Rajiv Kumar Jha (Verfasst von), Xueli Chen (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2019-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Combination chemotherapy has been proven to be an efficient strategy for the treatment of prostate cancer (PCA). However, the pharmacokinetic distinction between the relevant drugs is an insurmountable barrier to the realization of their synergistic use against cancer. To overcome the disadvantages...